32 results on '"Oster JP"'
Search Results
2. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study
- Author
-
Tiotiu, A, primary, Oster, JP, additional, Roux, PR, additional, Nguyen Thi, PL, additional, Peiffer, G, additional, Bonniaud, P, additional, Dalphin, JC, additional, and de Blay, F, additional
- Published
- 2020
- Full Text
- View/download PDF
3. Radiochimiothérapie optimisée pour le cancer bronchique non à petites cellules localement évolué
- Author
-
Quoix, E, primary, Moreau, L, additional, and Oster, JP, additional
- Published
- 1998
- Full Text
- View/download PDF
4. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
- Author
-
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, and Lebitasy MP
- Published
- 2011
- Full Text
- View/download PDF
5. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
- Author
-
Tiotiu A, Mendez-Brea P, Ioan I, Romero-Fernandez R, Oster JP, Hoang TC, Roux P, Ochoa-Gutierrez DC, Bonniaud P, de Blay F, and Gonzalez-Barcala FJ
- Subjects
- Humans, Omalizumab therapeutic use, Retrospective Studies, Anti-Asthmatic Agents therapeutic use, Asthma complications, Asthma drug therapy, Nasal Polyps complications, Nasal Polyps drug therapy, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Biological therapies are available for the treatment of the severe allergic asthma (SAA) with blood eosinophil count ≥ 0.3 × 10
9 /L. Several of them also showed benefits on nasal polyps (NP), one of the most frequent comorbidities of the severe asthma, but comparative studies on their effectiveness in the association SAA-NP are currently lacking. The aim of this study is to compare the effectiveness of benralizumab, mepolizumab and omalizumab in patients with SAA-NP in real-life settings. A retrospective, observational, multicenter real-life study was realized including patients with SAA-NP treated by benralizumab, mepolizumab or omalizumab for 6 months. We analysed the nasal and respiratory symptoms, the number of asthma attacks and salbutamol use/week, acute sinusitis and severe exacerbation rates, the asthma control score, the lung function parameters, the NP endoscopic score, the sinus imaging and the blood eosinophil count 6 months before and after treatment. Seventy-two patients with SAA-NP were included: 16 treated by benralizumab, 21 by mepolizumab and 35 by omalizumab. After 6 months of treatment, almost all studied parameters were improved (except sinus imaging) with a greater effect of omalizumab on the nasal pruritus (p = 0.001) and more benefits of benralizumab on exacerbations rate, asthma attacks per week and lung function (all p < 0.05). Benralizumab and mepolizumab were more effective to improve the NP endoscopic score and the blood eosinophil count (both p < 0.001). All three biological therapies showed effectiveness by improving asthma and nasal outcomes in patients with SAA-NP. Several differences have been found that should be confirmed by larger comparative studies., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
6. Phenotyping to Target Obstructive Sleep Apnoea Syndrom (OSAS) in adults patients with severe asthma.
- Author
-
Portel L, Parrat E, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, de Vecchi CA, Maurer C, Raherison C, and Debieuvre D
- Subjects
- Humans, Male, Adrenal Cortex Hormones, Cross-Sectional Studies, Obesity complications, Obesity epidemiology, Prospective Studies, Asthma diagnosis, Asthma epidemiology, Hypertension epidemiology, Sleep Apnea, Obstructive diagnosis, Sleep Apnea, Obstructive epidemiology, Sleep Apnea, Obstructive therapy
- Abstract
Background: Obstructive sleep apnoea syndrome (OSAS) and severe asthma are frequently associated. This article focuses on the relationship between severe asthma phenotypes and OSAS., Methods: FASE-CPHG was an observational, cross-sectional, prospective, multicentric study conducted in 104 non-academic hospitals from May-16 to July-17. 1465 patients with severe asthma were analysed and 1424 patients phenotyped. Clusters were compared for OSAS presence; independent factors associated with OSAS were identified by logistic regression., Results: 11% of patients with severe asthma reported OSAS. OSAS incidence differed according to asthma phenotypes. 98% of OSAS patients belonged to the "obese asthma" cluster, and none to the "early onset allergic asthma" cluster. Independent factors associated with OSAS were obesity (OR=5.782 [3.927-8.512]), male gender (OR=3.047 [2.059-4.510]), high blood pressure (OR=2.875 [1.978-4.181]), depression (OR=2.552 [1.607-4.050]), late-onset asthma (OR=1.789 [1.167-2.743]) and atopy (OR=0.622 [0.408-0.948]). Moreover, OSAS patients were more frequently treated with long-term oral corticosteroids (30% vs 15%, p < 0.0001), that may contribute to the high prevalence of obesity in this group of patients. They were more frequently uncontrolled (78% vs 69%, p = 0.03) and they engaged in low level physical activity (vs 80% vs 68% p ≤ 0.001)., Conclusion: Our study gives an innovative insight into OSAS associated with severe asthma. Most of patients with OSAS belonged to the cluster "obese asthma" and none to the cluster "early onset allergic asthma". In addition to male gender, arterial hypertension and depression, obese asthma, late onset asthma and non-atopic status were identified as specific risk factors. Oral corticosteroids seems to play a deleterious role. Phenotyping asthma can help physicians target severe asthmatic patients with OSAS and may avoid unnecessary examinations., Competing Interests: Conflict of Interest None., (Copyright © 2022. Published by Elsevier Masson SAS.)
- Published
- 2022
- Full Text
- View/download PDF
7. Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohort.
- Author
-
Calcaianu G, Degoul S, Michau B, Payen T, Gschwend A, Fore M, Iamandi C, Morel H, Oster JP, Bizieux A, Nocent-Ejnaini C, Carvallo C, Romanet S, Goupil F, Leurs A, Legrand MG, Portel L, Claustre J, Calcaianu M, Bresson D, and Debieuvre D
- Subjects
- Male, Humans, Middle Aged, Aftercare, Patient Discharge, Hospitalization, Disease Progression, Dyspnea, Lung diagnostic imaging, COVID-19 complications, COVID-19 epidemiology
- Abstract
Background: Even though COVID-19 clinical features, pathogenesis, complications, and therapeutic options have been largely described in the literature, long-term consequences in patients remain poorly known., Methods: The French, multicentre, non-interventional SISCOVID study evaluated lung impairment three (M3) and six months (M6) after hospital discharge in patients recovered from COVID-19. Evaluation was based on clinical examination, pulmonary function tests, and chest computed tomography (CT-scan)., Results: Of the 320 included patients (mean age: 61 years; men: 64.1%), 205 had had a severe form of COVID-19, being hospitalised in an intensive care unit (ICU), and requiring high flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation. At M6, 54.1% of included patients had persistent dyspnoea (mMRC score ≥1), 20.1% severe impairment in gas diffusing capacity (DL
CO <60% pred.), 21.6% restrictive ventilatory pattern (total lung capacity <80% pred.), and 40% a fibrotic-like pattern at CT-scan. Fibrotic-like pattern and restrictive ventilatory pattern were significantly more frequent in patients recovered from severe than non-severe COVID-19. Improved functional and radiological outcomes were observed between M3 and M6. At M6, age was an independent risk factor for severe DLco impairment and fibrotic-like pattern and severe COVID-19 form was independent risk factor for restrictive ventilatory profile and fibrotic-like pattern., Conclusion: Six months after discharge, patients hospitalised for COVID-19, especially those recovered from a severe form of COVID-19, frequently presented persistent dyspnoea, lung function impairment, and persistent fibrotic-like pattern, confirming the need for long-term post-discharge follow-up in these patients and for further studies to better understand long-term COVID-19 lung impairment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 SPLF and Elsevier Masson SAS. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
8. Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version.
- Author
-
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, and Didier A
- Subjects
- Adolescent, Adult, Child, Female, Follow-Up Studies, Humans, Pregnancy, Societies, Asthma diagnosis, Asthma epidemiology, Asthma therapy, Pulmonary Medicine
- Abstract
The therapeutic management strategy is based on the regular evaluation of the control of asthmatic disease, with an effective minimum dose research and the assessment of environmental factors, not to mention the important place of therapeutic education. These professional recommendations relate to the management and follow-up of adult and adolescent asthma patients aged 12 and over. The recommendations answer the following questions: 1. How to make the initial diagnosis of asthma? 2. What allergological check-up should be done in asthmatics 3. How to manage an asthma exacerbation? 4. How to manage difficult asthma? 5. What therapeutic strategies? 6. How to manage a woman's asthma during pregnancy? 7. Environmental factors in asthma management review., Competing Interests: Declaration of Competing Interest Over the last 5 years, M. Russier has received fees or funding for participation in conferences, communications, training activities, participation in expert panels from Astra Zeneca, Chiesi, Novartis and Sanofi. Over the last 5 years, M. Russier was principal investigator of clinical studies sponsored by AstraZeneca. Over the last 5 years, A. Lorenzo has received the following from Novartis: ERS congress invitation. Over the last 5 years, C. RAHERISON SEMJEN has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels, research activities from ALK, Astra Zeneca, Boeringher Ingelheim, Chiesi, GSK, Novartis and Sanofi. Over the last 5 years, L. Guilleminault has received fees or funding for participation in conferences, communications, training activities, research activities, participation in expert panels, writing of articles or documents, counselling and expertises from ALK, AstraZeneca, Bayer, Chiesi, GlaxoSmithKline, MSD, Novartis, Sanofi and Stallergènes. Over the last 5 years, I. BILLIART has received fees or funding for participation in training activities and expert panels from Novartis, GSK and AstraZeneca. Over the last 5 years, Cécile Chenivesse has received fees or funding from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Nouveau Souffle, Novartis, Sanofi-Regeneron, Pierre Fabre, Pfizer, Roche, Santelys and TEVA Over the last 5 years, C. Nocent-Ejnain has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels from GSK, AstraZeneca, Novartis, ALK, Mundipharma, Chiesi, Menhari, Sanofi, Isis Medical and sos oxygene. Over the last 5 years, A. DIDIER has received fees or funding for participation in conferences, participation in expert panels, counselling and expertise missions from AstraZeneca, GSK, Chiesi, Stallergènes, ALK, Novartis, Boehringer Ingelheim, BMS, Menarini, Sanofi and Zambon. The other authors state that they have no links of interest. The document was reviewed by the Scientific Council of the SPLF (B. Maitre, C. Leroyer) and the members of the review group: B. Stach, P. Bonniaud, D. Holtea, L. Portel., (Copyright © 2022 SPLF and Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. [Erratum to "Updated guidelines for management of asthmatic patients (from 12 years and older). Short version" [Rev. Mal. Respir. 38 (2021) e1-e13]].
- Author
-
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, and Didier A
- Published
- 2022
- Full Text
- View/download PDF
10. [Erratum to "Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version" [Rev. Mal. Respir. 38 (2021) 1048-1083]].
- Author
-
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, and Didier A
- Published
- 2022
- Full Text
- View/download PDF
11. [Severe adult asthma and treatment adherence: Results of the FASE-CPHG study].
- Author
-
Maurer C, Raherison-Semjen C, Lemaire B, Didi T, Nocent-Ejnaini C, Parrat E, Prudhomme A, Oster JP, Coëtmeur D, Debieuvre D, and Portel L
- Subjects
- Adrenal Cortex Hormones, Adult, Cross-Sectional Studies, Humans, Medication Adherence, Patient Compliance, Prospective Studies, Asthma drug therapy, Asthma epidemiology
- Abstract
Introduction: Data on severe asthma in France are scarce. The aim of this study was to evaluate adherence to asthma treatments and its determinants in a population of severe asthmatics., Methods: From May 2016 to June 2017, the French Collège des Pneumologues des Hôpitaux Généraux organized a large-scale prospective, cross-sectional, multicenter study on this topic; 1502 patients with severe asthma were included., Results: The average number of substantive treatments was 2.5±1.1. Assessed by self-questionnaire in 1289 patients, overall adherence was 64.8%, in good agreement with the findings of the pneumologist in charge (p<0.0001). Control of asthma according to the GINA criteria was more successful in compliant patients (p<0.01). In univariate analysis, the most compliant participants were frequent exacerbator patients (p=0.02), those with nasal polyposis (p=0.01) and those receiving an anticholinergic agent (p<0.01), anti-IgE biotherapy (p<0.0001) or oral corticosteroids (p<0.01). The least compliant participants were younger (p<0.0001), active smokers (p<0.001), with shorter average disease duration (24.2±15.7 vs 29.1±18.7 years, p<0.0001) and a lower number of substantive asthma treatments (2.2±1 vs 2.6±1, p<0.0001). In multivariate analysis, age, length of disease and anti-IgE treatment were the only factors affecting therapeutic compliance., Conclusion: In this large-scale study of severe asthmatic patients, 64.8% were compliant according to the MMAS-4© self-administered questionnaire and appeared to be better monitored according to the criteria defined in our study. Overall, adherence was more satisfactory among older patients and those whose disease had been evolving over a long period of time or were receiving anti-IgE biotherapy., (Copyright © 2021. Published by Elsevier Masson SAS.)
- Published
- 2021
- Full Text
- View/download PDF
12. [Updated guidelines for management of asthmatic patients (from 12 years and older). Short version].
- Author
-
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, and Didier A
- Subjects
- Humans, Anti-Asthmatic Agents therapeutic use, Asthma diagnosis, Asthma epidemiology, Asthma therapy
- Published
- 2021
- Full Text
- View/download PDF
13. [Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version].
- Author
-
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, and Didier A
- Subjects
- Adult, Child, Follow-Up Studies, Humans, Asthma diagnosis, Asthma therapy, Pulmonary Medicine
- Published
- 2021
- Full Text
- View/download PDF
14. FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis.
- Author
-
Raherison-Semjen C, Parrat E, Nocent-Eijnani C, Mangiapan G, Prudhomme A, Oster JP, Aperre de Vecchi C, Maurer C, Debieuvre D, and Portel L
- Subjects
- Adolescent, Adult, Age of Onset, Asthma epidemiology, Asthma physiopathology, Asthma, Aspirin-Induced diagnosis, Asthma, Aspirin-Induced epidemiology, Body Mass Index, Child, Cluster Analysis, Comorbidity, Eosinophilia diagnosis, Eosinophilia epidemiology, Female, Forced Expiratory Volume, France epidemiology, Humans, Lung physiopathology, Male, Middle Aged, Obesity diagnosis, Obesity epidemiology, Phenotype, Prospective Studies, Risk Factors, Severity of Illness Index, Young Adult, Asthma diagnosis
- Abstract
Background: In France, data regarding epidemiology and management of severe asthma are scarce. The objective of this study was to describe asthma phenotypes using a cluster analysis in severe asthmatics recruited in a real world setting., Methods: The study design was prospective, observational and multicentric. The patients included were adults with severe asthma (GINA 4-5) followed-up in French Non Academic Hospital between May 2016 and June 2017. One hundred and seven physicians included 1502 patients. Both sociodemographic and clinical variables were collected. Hierarchical cluster analysis was performed by the Ward method followed by k-means cluster analysis on a population of 1424 patients., Results: Five clusters were identified: cluster 1 (n = 690, 47%) called early onset allergic asthma (47.5% with asthma before 12 years), cluster 2 (n = 153, 10.5%): obese asthma (63.5% with BMI > 30 kg/m
2 ), cluster 3 (n = 299, 20.4%): late-onset asthma with severe obstructive syndrome (89% without atopy), cluster 4 (n = 143, 9.8%): eosinophilic asthma (51.7% had more than 500 eosinophils/mm3 ), and cluster 5 (n = 139, 9.5%): aspirin sensitivity asthma (63% had severe asthma attacks)., Conclusions: In our population of adults with severe asthma followed by pulmonologists, five distinct phenotypes were identified and are quite different from those mentioned in previous studies.- Published
- 2021
- Full Text
- View/download PDF
15. Erratum à « Prix du meilleur article original 2020 ».
- Author
-
Coëtmeur D, Parrat É, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, Appere De Vecchi C, Maurer C, Raherison C, Debieuvre D, and Portel L
- Published
- 2021
- Full Text
- View/download PDF
16. [Physical activity in severe asthma: Results of the FASE-CPHG Study].
- Author
-
Coëtmeur D, Parrat É, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, Vecchi CA, Maurer C, Raherison C, Debieuvre D, and Portel L
- Subjects
- Adolescent, Adult, Aged, Asthma pathology, Asthma rehabilitation, Body Mass Index, Comorbidity, Cross-Sectional Studies, Female, France epidemiology, Humans, Male, Middle Aged, Obesity complications, Obesity epidemiology, Practice Patterns, Physicians' statistics & numerical data, Severity of Illness Index, Surveys and Questionnaires, Young Adult, Asthma epidemiology, Exercise physiology
- Abstract
Introduction: Data on physical activity in severe asthma are scarce. From May 2016 to June 2017, 1502 adult patients with severe asthma visiting a pulmonologist practicing in one of the 104 non-academic hospitals participating in the study were included in this prospective, cross-sectional, multicenter study, provided they gave consent. Physical activity was classified according to 4 levels: 1 (no activity), 2 (occasional), 3 (regular), or 4 (frequent). Clinical and therapeutic parameters were described according to these levels., Results: Respectively, 440, 528, 323, and 99 patients had physical activity of level 1, 2, 3, and 4. The percentage of patients with controlled asthma increased with physical activity. Treatment adherence did not differ with physical activity. Percentages of obese patients, patients with FEV1 <60%, and patients with anxiety, depressive syndrome, gastro-esophageal reflux disease, arterial hypertension, diabetes, obstructive sleep apnoea-hypopnoea syndrome, and osteoporosis decreased with physical activity. Respiratory rehabilitation was offered to only 5% of patients., Conclusions: In this large study, physical activity is associated with disease control in severe asthma and with less comorbidity. Its practice should be encouraged and respiratory rehabilitation offered more often., (Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals.
- Author
-
Portel L, Parrat E, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, Aperre de Vecchi C, Maurer C, Raherison C, and Debieuvre D
- Abstract
Background: Real-world data describing management of patients with severe asthma are limited. To address this issue, we conducted FASE-CPHG (France Asthme Sevère - Collège des Pneumologues des Hôpitaux Généraux), a descriptive, multicentric, and observational cross-sectional study., Methods: French pulmonologists from nonacademic hospitals completed questionnaires on patient characteristics and ongoing asthma treatment for severe asthmatic patients observed during the inclusion period. In addition, we collected data from patients via self-assessment questionnaires., Findings: 104 physicians recruited 1502 patients within 1 year. The mean age of the 1465 patients analysed was 54.4±16.1 years. Severe asthmatic patients were more frequently female (63%), with a history of atopy (65%). Most patients remained poorly controlled or uncontrolled, with an important difference between physicians' opinion and the Global Initiative for Asthma criteria (63% versus 96%). The most common comorbidities included ear, nose and throat diseases (59% of cases); anxiety (40%); and gastro-oesophageal reflux disease (39%). Allergic sensitisation tests and/or blood eosinophil count evaluation, and spirometry were performed in 92% and 98% of patients, respectively. The mean eosinophil count and total serum IgE were 437 cells·mm
-3 and 546 UI·L-1 , respectively. In addition to high doses of inhaled corticosteroids plus long-acting β2 -agonists, patients were receiving leukotriene receptor antagonists (52%), anticholinergic drugs (34%), anti IgE (27%) and oral corticosteroids (17%); 65% adhered to their treatment., Interpretation: This study provides insight into the characteristics and management of severe asthma in France and may help improve knowledge on this pathology, which represents a high burden to healthcare., Competing Interests: Conflict of interest: L. Portel has nothing to disclose. Conflict of interest: E. Parrat has nothing to disclose. Conflict of interest: C. Nocent-Ejnaini has nothing to disclose. Conflict of interest: G. Mangiapan has nothing to disclose. Conflict of interest: A. Prud'homme has nothing to disclose. Conflict of interest: J-P. Oster has nothing to disclose. Conflict of interest: C. Aperre de Vecchi has nothing to disclose. Conflict of interest: C. Maurer has nothing to disclose. Conflict of interest: C. Raherison has nothing to disclose. Conflict of interest: D. Debieuvre has nothing to disclose., (Copyright ©ERS 2019.)- Published
- 2019
- Full Text
- View/download PDF
18. [Therapeutic strategies in patients undergoing surgery for non-small cell lung cancer. Results of the ESCAP-2011-CPHG study, promoted by the French College of General Hospital Respiratory Physicians (CPHG)].
- Author
-
Pinquié F, Goupil F, Oster JP, Dixmier A, Renault PA, Lévy A, Mathieu JP, Paillot N, Goutorbe FC, Masson P, Molinier O, Debieuvre D, and Grivaux M
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung epidemiology, Cohort Studies, Female, Follow-Up Studies, France epidemiology, Hospitals, General organization & administration, Hospitals, General statistics & numerical data, Humans, Lung Neoplasms diagnosis, Lung Neoplasms epidemiology, Male, Middle Aged, Pneumonectomy methods, Pneumonectomy statistics & numerical data, Pulmonary Medicine organization & administration, Societies, Medical organization & administration, Societies, Medical standards, Workforce, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms surgery, Lung Neoplasms therapy, Practice Patterns, Physicians' statistics & numerical data, Pulmonary Medicine methods
- Abstract
Background: The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patients undergoing surgical management of a non-small cell lung cancer (NSCLC)., Methods: A prospective multicentre study was conducted in 53 French general hospitals. For each patient with lung cancer diagnosed in 2010, a standardised form was completed following each change in treatment strategy up to 2 years after diagnosis., Results: Overall, 3418 of the 3943 included patients had NSCLC. 741 patients (21.7%) underwent curative surgery (stage 0-II, IIIA, IIIB, and IV: 65%, 27%, 3% and 5%, respectively). The therapeutic strategy changed less often in surgical than non-surgical patients and average follow-up time was longer: 23.3 months (SD: 9.3) versus 10.4 months (SD: 9.5) for non-surgical patients. Among patients with a surgical first strategy (92.6% of surgical patients as a whole), 56.9% did not receive any other treatment, 34.7% received chemotherapy, 5.9% radio-chemotherapy, 2.6% radiotherapy. At the end of follow-up, 55.8% were still alive without any other strategy, 13.1% had died, and 31.1% had received at least one more strategy. Among patients with a surgical second strategy, 63% had received chemotherapy alone during the first strategy., Conclusions: ESCAP -2011- CPHG assessed everyday professional practice in the surgical management of NSCLC in general hospitals. It pointed out the discrepancies between current guidelines and the therapeutic strategies applied in real life conditions., (Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
- Author
-
Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, and Westeel V
- Subjects
- Aged, Aged, 80 and over, Decision Making, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Europe, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Time Factors, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Paclitaxel administration & dosage
- Abstract
In the Intergroupe Francophone de Cancérologie Thoracique 0501 trial the carboplatin-paclitaxel chemotherapy increased toxicity (most frequent, decreased neutrophil count, asthenia). We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89 years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. HRQoL was assessed by means of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline, week 6 and week 18.Using a five-point decrease as the minimal clinically important difference, patients treated with the chemotherapy doublet exhibited a significant longer time until definitive deterioration (TUDD) for two HRQoL dimensions: physical functioning (median TUDD: 2.04 for the doublet versus 1.71 months for monotherapy; log-rank p=0.01) and nausea and vomiting (median: not reached versus 4.83, respectively; log-rank p=0.046). Cox multivariate analysis revealed the carboplatin and paclitaxel arm to be independently associated with longer TUDD for these two HRQoL dimensions. In addition, TUDD didn't significantly differ between the two arms for all the other HRQoL dimensions.The chemotherapy doublet did not reduce TUDD in elderly patients with advanced NSCLC. Moreover, TUDD was prolonged for two HRQoL dimensions, namely physical functioning and nausea and vomiting., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
20. The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.
- Author
-
Debieuvre D, Oster JP, Riou R, Berruchon J, Levy A, Mathieu JP, Dumont P, Leroy-Terquem E, Tizon-Couetil V, Martin F, and Grivaux M
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung mortality, Female, France epidemiology, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Mortality trends, Prospective Studies, Sex Factors, Smoking epidemiology, Smoking mortality, Carcinoma, Non-Small-Cell Lung epidemiology, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms epidemiology
- Abstract
Objectives: To evaluate the impact of epidemiological changes observed in 10 years in men with NSCLC on 1-year mortality; to compare prognosis factors of 1-year mortality according to gender., Material and Methods: The French College of General Hospital Respiratory Physicians conducted two prospective epidemiological multicentre studies at a 10-year interval (KBP-2000-CPHG and KBP-2010-CPHG). These studies included all adult patients with primary lung cancer histologically or cytologically diagnosed between 1(st) January and 31(st) December for the years 2000 and 2010, managed in the pneumology department of the participating hospitals. A standardised form was completed for each patient. A steering committee checked recruitment exhaustiveness. Vital status 1 year after diagnosis was collected., Results: In 2000 and 2010 respectively, 137 and 104 centres included 3921 and 4597 men and 748 and 1486 women with NSCLC. In 2010 compared to 2000, male patients were older but had better performance status (PS); they were less frequently ever-smokers and heavy smokers; their cancer (usually diagnosed at advanced stage) was more often adenocarcinoma (p<0.0001). In 10 years, 1-year mortality has significantly decreased in men (from 61.2% to 56.6%, p<0.0001) and in women (from 58.1% to 50.9%, p<0.0001), but remained higher in men than in women leading to increased difference between men and women. Decreased 1-year mortality remained statistically significant after adjustment on age, PS, smoking, and histology (men: OR=0.81, 95% CI=0.73-0.90, p<0.0001; women: 0.71, 0.57-0.88, p<0.002). Active smoking was not a prognosis factor in men (OR=1.04, CI=0.79-1.37, p=0.78); age (>75 years) had less impact on mortality in men than in women (men: OR=1.43, CI=1.22-1.67, p ≤ 0.0001; women: OR=2.32, CI=1.71-3.15; p<0.0001)., Conclusions: The improved 1-year survival in 2010 as compared with 2000 was independent of age, smoking, PS, and histology, suggesting that it reflected new treatment and strategy efficacy. One-year mortality remains higher in men than in women., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
21. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
- Author
-
Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, and Zalcman G
- Subjects
- Adult, Aged, Angiogenesis Inhibitors adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab adverse effects, Cisplatin therapeutic use, Cyclophosphamide therapeutic use, Disease Progression, Disease-Free Survival, Epirubicin therapeutic use, Etoposide therapeutic use, Female, France, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Proportional Hazards Models, Risk Factors, Small Cell Lung Carcinoma mortality, Small Cell Lung Carcinoma pathology, Time Factors, Treatment Outcome, Young Adult, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab therapeutic use, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy
- Abstract
Background: This randomized phase II-III trial sought to evaluate the efficacy and safety of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung cancer (SCLC)., Patients and Methods: Enrolled SCLC patients received two induction cycles of CT. Responders were randomly assigned 1:1 to receive four additional cycles of CT alone or CT plus Bev (7.5 mg/kg), followed by single-agent Bev until progression or unacceptable toxicity. The primary end point was the percentage of patients for whom disease remained controlled (still in response) at the fourth cycle., Results: In total, 147 patients were enrolled. Partial response was observed in 103 patients, 74 of whom were eligible for Bev and randomly assigned to the CT alone group (n = 37) or the CT plus Bev group (n = 37). Response assessment at the end of the fourth cycle showed that disease control did not differ between the two groups (89.2% versus 91.9% of patients remaining responders in CT alone versus CT plus Bev, respectively; Fisher's exact test: P = 1.00). Progression-free survival (PFS) since randomization did not significantly differ, with a median PFS of 5.5 months [95% confidence interval (CI) 4.9% to 6.0%] versus 5.3 months (95% CI 4.8% to 5.8%) in the CT alone and CT plus Bev groups, respectively [hazard ratio (HR) for CT alone: 1.1; 95% CI 0.7% to 1.7%; unadjusted P = 0.82]. Grade ≥2 hypertension and grade ≥3 thrombotic events were observed in 40% and 11% of patients, respectively, in the CT plus Bev group. Serum vascular endothelial growth factor (VEGF) and soluble VEGF receptor titrations failed to identify predictive biomarkers., Conclusion: Administering 7.5 mg/kg Bev after induction did not improve outcome in extensive SCLC patients., (© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
22. Standardization of an ash (Fraxinus excelsior) pollen allergen extract.
- Author
-
Hrabina M, Purohit A, Oster JP, Papanikolaou I, Jain K, Pascal P, Sicard H, Gouyon B, Moingeon P, Pauli G, and André C
- Subjects
- Adolescent, Adult, Allergens adverse effects, Allergens analysis, Allergens immunology, Antigens, Plant, Calibration, Humans, Immunoglobulin E immunology, Middle Aged, Pollen immunology, Reference Standards, Rhinitis, Allergic, Seasonal immunology, Fraxinus immunology, Pollen chemistry, Skin Tests standards
- Abstract
Background: Ash tree (Fraxinus excelsior) is the main representative of the Oleaceae family in temperate zones. Diagnosis of ash pollen allergy is made difficult due to (1) an overlapping pollinization period with Betulaceae, (2) non-inclusion in current diagnostic assays, and (3) some cross- reactivity with minor allergens from Betulaceae. The aim of this study was to calibrate an ash pollen in-house reference preparation (IHRP) in allergic patients in order to produce standardized products for diagnosis and immunotherapy purposes., Methods: Ash pollen IHRP was extracted, ultrafiltered and freeze dried. Allergens in the extract were detected after 2-dimensional PAGE using specific sera and a monoclonal antibody. The Fra e 1 content of IHRP was evaluated by quantitative immunoprint. Forty-eight subjects from the North-East of France exhibiting clinical symptoms, a positive skin test and specific IgE levels > or =class 2 to ash pollen were recruited. IgE immunoprints were performed to select patients sensitized to the ash Fra e 1 allergen as opposed to cross-reacting allergens. Serial 10-fold dilutions of the IHRP were tested by skin prick tests in order to determine the concentration inducing a geometrical mean wheal diameter of 7 mm, said to correspond to an index of reactivity (IR) of 100 per millilitre., Results: IgE-reactive molecules in IHRP comprise Fra e 1, Fra e 2, a 9-kDa molecule (presumably Fra e 3), as well as a doublet at 15 kDa and high molecular weight allergens. The 100 IR concentration of IHRP inducing a geometrical mean wheal diameter of 7 mm in 22 patients sensitized to Fra e 1 corresponds to the 1/126 (w/v) extraction ratio (i.e. 259 microg/ml of protein by Bradford) and contains 17 microg/ml of Fra e 1. The variability in total activity of 5 batches of standardized extracts was found to be significantly reduced when compared with 7 non-standardized extracts., Conclusion: An ash pollen IHRP was defined and molecularly characterized. Its successful standardization at 100 IR/ml in patients specifically sensitized to Fra e 1 allowed a skin reactivity-based calibration in properly diagnosed patients. Such a standardized ash pollen extract is a reliable tool to support immunotherapy of ash pollen allergy., (Copyright 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF
23. Nerve growth factor levels and localisation in human asthmatic bronchi.
- Author
-
Olgart Höglund C, de Blay F, Oster JP, Duvernelle C, Kassel O, Pauli G, and Frossard N
- Subjects
- Adult, Asthma pathology, Bronchi pathology, Bronchoalveolar Lavage Fluid chemistry, Bronchoalveolar Lavage Fluid cytology, Connective Tissue chemistry, Enzyme-Linked Immunosorbent Assay, Epithelium chemistry, Female, Humans, Immunohistochemistry, Male, Muscle, Smooth chemistry, Asthma metabolism, Bronchi chemistry, Nerve Growth Factor analysis
- Abstract
Nerve growth factor (NGF) has recently been suggested to be an important mediator of inflammation. In support of this, serum levels of NGF have been shown to be enhanced in asthmatics. However, it has not yet been shown whether the levels of NGF are also altered locally in asthmatic airways, when compared with healthy subjects, and the localisation of potential sources of NGF in the human bronchus have not yet been described. The aim of the present study was to assess NGF levels in bronchoalveolar lavage fluid (BALF) from asthmatics and to compare them to those of control subjects. Furthermore, the authors wanted to localise potential sources of NGF in bronchial tissue, and to number NGF-immunopositive infiltrating cells in the bronchial submucosa. BALF and bronchial biopsies were obtained from seven control subjects and seven asthmatic patients by fibreoptic bronchoscopy. NGF protein levels were quantified by enzyme-linked immunosorbent assay in BALF. NGF localisation was examined by immunohistochemistry on bronchial biopsy sections. The asthmatics exhibited significantly enhanced NGF levels in BALF. Intense NGF-immunoreactivity was observed in bronchial epithelium, smooth muscle cells and infiltrating inflammatory cells in the submucosa, and to a lesser extent in the connective tissue. The asthmatics exhibited a higher number of NGF-immunoreactive infiltrating cells in the bronchial submucosa than control subjects. This study provides evidence that nerve growth factor is locally produced in the airways, and shows that this production is enhanced in asthmatics. These findings suggest that nerve growth factor is produced by both structural cells and infiltrating inflammatory cells in human bronchus in vivo, and the authors suggest that the increase in nerve growth factor protein in bronchoalveolar lavage fluid observed in asthmatic patients may originate both from structural cells, producing increased nerve growth factor levels in inflammatory conditons, and from the increase in nerve growth factor-immunopositive cells determined in the bronchial submucosa.
- Published
- 2002
- Full Text
- View/download PDF
24. The allergen profile of ash (Fraxinus excelsior) pollen: cross-reactivity with allergens from various plant species.
- Author
-
Niederberger V, Purohit A, Oster JP, Spitzauer S, Valenta R, and Pauli G
- Subjects
- Adolescent, Adult, Animals, Antibody Specificity immunology, Cross Reactions immunology, Female, Humans, Hypersensitivity immunology, Immunization, Immunoblotting, Immunoglobulin E analysis, Immunoglobulin E immunology, Male, Middle Aged, Sensitivity and Specificity, Serologic Tests, Skin Tests, Allergens classification, Allergens immunology, Fraxinus classification, Fraxinus immunology, Pollen classification, Pollen immunology
- Abstract
Background: Ash, a wind-pollinated tree belonging to the family Oleaceae, is distributed world-wide and has been suggested as a potent allergen source in spring time., Objective: The aim of this study was to determine the profile of allergen components in ash pollen in order to refine diagnosis and therapy for patients with sensitivity to ash pollen, Methods: The IgE reactivity profile of 40 ash pollen-allergic patients was determined by immunoblotting. Antibodies raised to purified pollen allergens from tree and grass pollens were used to identify cross-reactive structures in ash pollen extract. IgE immunoblot inhibition studies were performed with recombinant and natural pollen allergens to characterize ash pollen allergens and to determine the degree of cross-reactivity between pollen allergens from ash, olive, birch, grasses and weeds., Results: The allergen profile of ash pollen comprises Fra e 1, a major allergen related to the major olive allergen, Ole e 1, and to group 11 grass pollen allergens, the panallergen profilin, a two EF-hand calcium-binding protein, a pectinesterase-like molecule and an allergen sharing epitopes with group 4 grass pollen allergens. Thus, the relevant allergens of ash are primarily allergens that share epitopes with pollen allergens from other tree, grass and weed species., Conclusions: Allergic symptoms to ash pollen can be the consequence of sensitization to cross-reactive allergens from other sources. The fact that ash pollen-allergic patients can be discriminated on the basis of their specific IgE reactivity profile to highly or moderately cross-reactive allergens has implications for the selection of appropriate forms of treatment.
- Published
- 2002
- Full Text
- View/download PDF
25. [Nasosinusal sarcoidosis: 13 cases].
- Author
-
Braun JJ, Bourjat P, Oster JP, Pauli G, Quoix E, and Gentine A
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Diagnosis, Differential, Endoscopy, Ethmoid Sinus, Female, Humans, Male, Maxillary Sinus, Middle Aged, Recurrence, Sphenoid Sinus, Tomography, X-Ray Computed, Nose Diseases diagnosis, Nose Diseases drug therapy, Paranasal Sinus Diseases diagnosis, Paranasal Sinus Diseases drug therapy, Sarcoidosis diagnosis, Sarcoidosis drug therapy
- Abstract
We report 13 cases of nasosinusal sarcoidosis. Sarcoidosis is a chronic, non caseating granulomatous disease. Nasosinusal involment is rare or exceptional and may be isolated (1 case in our series) or associated (12 cases in our series) with other lesions of the chest, skin, liver, spleen, bone, eyes, salivary glands, peripheral lymph nodes or with neurosarcoidosis. The clinical and CT features are various and often non specific. Nasal biopsy guided by physical examination is easy and constitute the main diagnostic criterion. The course of nasosinusal sarcoidosis is variable and no standard treatment has been established. Response to local or systemic corticosteroid therapy is also variable. The recurrence is frequent after tapering off or interrupting corticosteroids that also have important side effects.
- Published
- 2001
26. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
- Author
-
Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, and Pauli G
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell enzymology, Carcinoma, Small Cell mortality, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms enzymology, Lung Neoplasms mortality, Male, Middle Aged, Prognosis, Biomarkers, Tumor metabolism, Carcinoma, Small Cell diagnosis, L-Lactate Dehydrogenase metabolism, Lung Neoplasms diagnosis, Phosphopyruvate Hydratase metabolism, Platinum Compounds therapeutic use
- Abstract
The influence of pretreatment serum levels of lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) on survival was investigated in a series of 263 consecutive patients with small-cell lung cancer. LDH was elevated in one-half of the patients, NSE in 79%. Both were significantly higher when the disease was considered extensive than when it was limited. The markers were significantly correlated (r= 0.54, P=1.03 x 10(-20)), and both had a significant impact on survival in the univariate analysis. The multivariate survival analysis of the entire population showed that LDH, along with performance status, extent of disease, and albumin, was a more important prognostic factor than NSE. Only when LDH was removed from the model did NSE become an independent prognostic factor. In the separate multivariate survival analyses of limited and extensive disease, LDH remained an independent prognostic factor. For extensive disease, NSE did not even appear in the model when LDH was excluded; for limited stage disease, NSE did become a weak independent prognostic factor when LDH was excluded. In conclusion, LDH, which is less expensive to assay than NSE, is also a stronger independent prognostic factor for small-cell lung cancer and should be part of the initial work-up. In clinical trials, stratification for LDH levels should be considered because of its prognostic weight.
- Published
- 2000
- Full Text
- View/download PDF
27. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
- Author
-
Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D, and Valenta R
- Subjects
- Adolescent, Adult, Antigens, Plant, Dose-Response Relationship, Immunologic, Female, France, Humans, Immunoglobulin E analysis, Immunoglobulin G analysis, Intradermal Tests, Male, Middle Aged, Pollen immunology, Protein Structure, Quaternary, Recombinant Proteins genetics, Recombinant Proteins immunology, Skin Tests, Allergens, Hypersensitivity, Immediate immunology, Plant Proteins genetics, Plant Proteins immunology
- Abstract
Background: Bet v 1, the major allergen in birch pollen, is recognized by more than 90% of patients allergic to birch in northern and central Europe. Immunotherapy is commonly performed with birch pollen extracts. Recently, hypoallergenic derivatives of Bet v 1 (rBet v 1 fragments, rBet v 1 dimer and trimer) were constructed and purified., Objective: Our aim was to compare the allergenic activity of wild-type rBet v 1 with recombinant Bet v 1 derivatives (rBet v 1 fragments, dimer and trimer) with potentially reduced anaphylactic activity by skin testing in a French population., Methods: Among the 36 birch pollen allergic patients included in the study, 29 were tested by skin prick testing and 30 by intradermal injections with purified monosubstances: rBet v 1 fragments (F1: aa1-74 and F2: aa75-160), Bet v 1 dimer and trimer. Intradermal tests were performed by the end-point intradermal titration method. Eight of the intradermally-tested patients were previously hyposensitized. Tests were performed over a period of 6 months (before, during and after birch pollen season); Bet v 1-specific IgE and IgG4 subclass responses were measured by immunoblotting and ELISA., Results: All patients showed lower reactivity with the modified rBet v 1 allergens, both in skin prick and intradermal tests. In 25 and 23 out of 29 patients the lowest concentration of fragment 1 and 2, respectively, resulting in a positive prick test was 100-fold higher than the lowest concentration of monomer resulting in a positive prick test. For dimer it was 100-fold or more in 25 out of 29 patients, and for trimer it was 100-fold or superior in 26 out of 29 patients. By intradermal testing, the end-point concentration was 160-fold higher for trimer than for monomer in 24 patients and 40-fold higher in five patients. For the two fragments the end-point concentration was 160-fold higher in 20 out of 22 patients., Conclusion: Genetically modified hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 showed reduced capacity to induce immediate type skin reactions. They may represent candidate molecules for immunotherapy of birch pollen allergy with reduced risk of anaphylactic side-effects.
- Published
- 2000
- Full Text
- View/download PDF
28. Genetics and specific immune response in allergy to birch pollen and food: evidence of a strong, positive association between atopy and the HLA class II allele HLA-DR7.
- Author
-
Sénéchal H, Geny S, Desvaux FX, Busson M, Mayer C, Aron Y, Oster JP, Bessot JC, Peltre G, Pauli G, and Swierczewski E
- Subjects
- Adult, Alleles, Antibody Formation, Antigens, Plant, Female, Genetic Predisposition to Disease, Histocompatibility Antigens Class II genetics, Histocompatibility Testing, Humans, Hypersensitivity, Immediate genetics, Male, Rhinitis, Allergic, Seasonal genetics, Allergens, Food Hypersensitivity genetics, Food Hypersensitivity immunology, HLA-DR7 Antigen genetics, Plant Proteins immunology, Pollen immunology, Rhinitis, Allergic, Seasonal immunology
- Abstract
Background: In some geographic areas birch pollen represents the most prominent cause for airborne allergic diseases. Up to 70% of patients allergic to birch pollen are hypersensitive to fruits, especially apples. Associations have been found, in some instances, with a sensitivity to aeroallergens and HLA class II genes., Objectives: We investigated whether susceptibility or resistance to birch pollen allergy with and without food allergy was associated with HLA class II genes., Methods: Blood samples were obtained from 2 groups of unrelated European-born white adults: 42 atopic patients (31 of them with asthma) and 42 healthy control subjects with no personal or familial history of asthma or atopy. Their antibody responses to birch pollen, apples, grass, and weed pollens were evaluated by skin tests, RASTs, and immunoprints. Genomic DNA was extracted from PBLs. The exons of DQA1, DQB1, DRB1, and DPB1 genes were selectively amplified by using the PCR method. Genotyping was carried out by digestion of the amplified DNA products with allele-specific endonucleases (PCR-RFLP), which recognize allelic variations in the polymorphic exon., Results: We found no significant differences in the frequency of DPB1 alleles between patients and control subjects. HLA class II DR4 and/or DR7 alleles were present in 42.6% of the patients and in only 2.4% of the healthy subjects. These results confirm a previous study of a group of polysensitized atopic patients, which showed that DR4 and DR7 alleles were rare in healthy control subjects and frequently observed in atopic subjects with or without concomitant asthma., Conclusion: We conclude that the allele HLA-DR7 is significantly involved in the presentation of apple and pollen allergens. However, we suggest that this susceptibility is more related to atopy than to specific responses to allergens.
- Published
- 1999
- Full Text
- View/download PDF
29. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives.
- Author
-
Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, Kraft D, and Valenta R
- Subjects
- Allergens genetics, Allergens therapeutic use, Antigens, Plant, Genetic Engineering, Humans, Hypersensitivity immunology, Plant Proteins genetics, Plant Proteins therapeutic use, Recombinant Proteins genetics, Recombinant Proteins immunology, Recombinant Proteins therapeutic use, Allergens immunology, Desensitization, Immunologic, Hypersensitivity drug therapy, Plant Proteins immunology
- Published
- 1999
- Full Text
- View/download PDF
30. Skin testing with wild-type recombinant birch pollen allergens and hypoallergenic modified molecules.
- Author
-
Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, Kraft D, and Valenta R
- Subjects
- Allergens adverse effects, Antigens, Plant, Humans, Recombinant Proteins adverse effects, Recombinant Proteins immunology, Skin Tests, Allergens immunology, Plant Proteins immunology
- Abstract
Unlabelled: Our aim was to compare the allergenic activity of wild type rBet v 1 with recombinant Bet v 1 derivatives (rBet v 1 fragments, dimer and trimer) with potentially reduced anaphylactic activity by skin testing in a French population., Methods: Among the 36 birch pollen allergic patients included in the study, 29 were tested by skin prick testing and 30 by intradermal injections with purified monosubstances: rBet v 1 fragments (F1: aa1-74 and F2: aa75-160), Bet v 1 dimer and trimer. Intradermal tests were performed by the endpoint intradermal titration method. Tests were performed over a period of 6 months (before, during and after birch pollen season)., Results: All patients showed lower reactivity with the modified rBet v 1 allergens, both in skin prick- and intradermal tests. In 25 and 23 out of 29 patients the lowest concentration of fragment 1 and 2 respectively, resulting in a positive prick test was 100 fold higher than the lowest concentration of monomer resulting in a positive prick test. For dimer it was 100 fold or more in 25 out of 29 patients, and for trimer it was 100 fold or superior in 26 out of 29 patients. By intradermal testing, the end point concentration was 160 fold higher for trimer than for monomer in 24 patients and 40 fold higher in 5 patients. For the 2 fragments the end point concentration was 160 fold higher in 20 out of 22 patients., Conclusion: rBet v 1 fragments and trimer may represent candidate molecules for immunotherapy of birch pollen allergy with reduced risk of anaphylactic side effects.
- Published
- 1999
31. [Radiochemotherapy and radiosensitization for locally advanced non-small-cell bronchial cancer].
- Author
-
Quoix E, Moreau L, and Oster JP
- Subjects
- Combined Modality Therapy, Humans, Radiotherapy Dosage, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Bronchogenic drug therapy, Carcinoma, Bronchogenic radiotherapy, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Radiation-Sensitizing Agents therapeutic use
- Abstract
Combined chemotherapy and radiotherapy can improve the survival of patients with locally advanced non-small cell lung cancer, when compared to irradiation alone. This survival benefit is essentially due to an increased control of distant micrometastases, whereas local control remains poor. In order to improve local control, new radiotherapy modalities such as 3D conformal treatment, hyperfractionation or accelerated hyperfractionation, are under development. Cytotoxic drugs given at low doses concomitantly to radiotherapy may act as radiosensitizers on the primary tumor. Concomitant chemotherapy at cytotoxic doses and radiotherapy would also allow better control on micrometastases and better local control due to radiosensitization by chemotherapy. However, the concomitant use of chemotherapy and radiotherapy is limited by increased toxicity on normal tissues, more particularly on the esophagus. Randomized comparisons of these modalities versus induction chemotherapy followed by radiotherapy are needed to determine the optimal treatment sequence.
- Published
- 1998
- Full Text
- View/download PDF
32. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies.
- Author
-
Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft D, and Valenta R
- Subjects
- Adult, Antibody Specificity, Antigens, Plant, Female, Food Hypersensitivity diagnosis, Food Hypersensitivity immunology, Humans, Male, Microfilament Proteins immunology, Plant Proteins immunology, Profilins, Recombinant Proteins administration & dosage, Recombinant Proteins immunology, Rhinitis, Allergic, Seasonal immunology, Allergens administration & dosage, Contractile Proteins, Intradermal Tests, Microfilament Proteins administration & dosage, Plant Proteins administration & dosage, Rhinitis, Allergic, Seasonal diagnosis
- Abstract
Objective: This study assesses the value of two recombinant birch allergens for diagnosis of patients sensitized to birch pollen with or without associated food allergy., Methods: Fifty-one patients with positive skin test responses to Betulaceae and seven nonallergic control subjects were investigated; specific IgE antibodies were evaluated by specific immunoassay and blot immunodetection., Results: Among 51 patients, 47 reacted to rBet v 1 and 10 to rBet v 2. Seven patients reacted to both recombinant allergens. In skin prick tests we found a correlation between the wheal produced by the commercial birch extract and the wheal produced by rBet v 1. Among 47 patients with positive test responses to rBet v 1, 83% had IgE binding to the Bet v 1 protein as determined by immunoblotting. Among 10 patients sensitized to rBet v 2, six had IgE binding to Bet v 2. Eleven patients with negative results, as determined by immunoblotting, had low levels of birch IgE in the sera (less than 10 kU/L) and low concentrations of IgE to rBet v 1 or rBet v 2 in ELISA. The nonallergic control subjects (n = 7) did not react to rBet v 1 or rBet v 2 in skin prick tests, nor did they have detectable amounts of specific IgE to rBet v 1 or rBet v 2. Histamine release tests confirmed sensitization to Bet v 1 in two patients with discordant results; for Bet v 2, one patient had positive results only at a high concentration, and one had results that remained negative. Thirty-four patients had birch pollinosis, and all reacted to rBet v 1. Patients who were monosensitized to birch never reacted to rBet v 2. Sensitization to rBet v 2 was only found in patients who reacted to other pollens (mainly grass). Twenty-nine patients demonstrated allergy to apples, cherries, or hazelnuts; and all reacted to rBet v 1. Among 11 patients with allergy to Umbelliferae, only three reacted to rBet v 2., Conclusions: Use of the two recombinant allergens (rBet v 1 and rBet v 2) always permits the diagnosis of birch sensitization. Sensitization to rBet v 1 is specific for birch and Rosaceae allergies, whereas sensitization to birch profilin, Bet v 2, is encountered in multisensitized subjects and is not always related to Umbelliferae allergy.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.